Presentation of Xbrane Biopharma’s interim report January – September 2022 on October 28, 2022
Other Corporate Information
Xbrane Biopharma AB, (publ) ("Xbrane" eller "Bolaget") (Nasdaq Stockholm: XBRANE) today hosted a teleconference for investors, analysts and media.
Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, presented the interim report January – September 2022, followed by a Q&A session.
As some technical issues were experienced pls follow the link to see the recorded version of the presentation.
Please follow the link below: